6.1.2025 14:57:26 CET | Thor Medical ASA | Annen informasjonspliktig regulatorisk informasjon
Oslo, Norway, 6 January 2025
Reference is made to stock exchange announcement by Thor Medical ASA (the “Company”) on 16 December 2024 regarding the notice of an extraordinary general meeting of the Company and the stock exchange notice on 12 December 2024 regarding the completion of a private placement (the “Private Placement”).
The extraordinary general meeting in the Company was held today 6 January 2025. All items on the agenda were approved by the general meeting as proposed the board, including i) the issuance of the 23,396,380 new shares (the “Offer Shares”) in tranche 2 (“Tranche 2”) of the Company’s completed Private Placement, and ii) granting the board of directors an authorisation to increase the Company’s share capital by up to NOK 2,200,000, in connection with the contemplated subsequent offering (the “Subsequent Offering”).
The Offer Shares is expected to be issued and registered in the Norwegian Register of Business Enterprises after the Company has published a prospectus for the listing of the Offer Shares. The prospectus is expected to be published on or about 10 January 2025.
Settlement of the Offer Shares in Tranche 2 is expected to take place on or about 8 January 2025. The Offer Shares will be settled through a delivery versus payment transaction with existing and unencumbered shares in the Company that are admitted to trading on Euronext Oslo Børs pursuant to a share lending arrangement between the Company, Carnegie AS and Scatec Innovation AS as the lender.
A detailed description of the Subsequent Offering, including the terms and conditions, as well as factors to consider when subscribing for shares in the Subsequent Offering, will be disclosed in an offer and listing prospectus to be published before the start of the subscription period for the Subsequent Offering. It is expected that the subscription period for the Subsequent Offering will last from 13 January 2025 at 09:00 (CET) to 24 January 2025 at 12:30 (CET), pending the approval and publication of the prospectus.
After the general meeting, the chairperson of the board of the Company, Ludvik Sandnes, informed the participants that he had notified the Company’s nomination committee of his decision not to seek re-election at the annual general meeting of the Company.
The minutes are attached hereto and are also available on https://www.thormedical.no/.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
CONTACTS
Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
Vedlegg
Last ned som PDF.pdf
Minutes from extraordinary general meeting 6 January 2025.pdf
